Evercore ISI Group has initiated coverage on Inspire Medical Systems Inc (INSP) with an Outperform rating, marking the firm's first assessment of the company's investment potential. This evaluation is based on comprehensive research into the company's business model, industry dynamics, and growth prospects.
Inspire Medical Systems, headquartered in Golden Valley, Minnesota, specializes in innovative, minimally invasive solutions for patients with obstructive sleep apnea. The company’s proprietary Inspire therapy, which is FDA, EU MDR, and PDMA-approved, provides a safe and effective treatment for moderate to severe cases of this condition. Inspire sells its systems through a direct sales force targeting hospitals and ambulatory surgery centers in the United States, as well as select markets in Europe and Japan.
As of September 1, 2025, Inspire Medical Systems Inc is trading at $89.88, with a market capitalization of $2.4 billion. The company has a trailing twelve months (TTM) price-to-earnings (P/E) ratio of 53.89 and earnings per share (EPS) of 1.47. Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of $0.33 and revenue of $249 million.
Analyst ratings and price targets reflect professional opinions based on research and financial models. While these assessments can provide valuable insights, they are based on assumptions and estimates that may not always materialize. Therefore, investment decisions should incorporate a range of factors, including company fundamentals and broader industry trends.
The recent analyst consensus indicates a Buy rating, with 4 Strong Buy, 10 Buy, and 12 Hold recommendations among a total of 26 analysts. This update provides insight into the evolving perspectives on Inspire Medical Systems as it navigates the competitive landscape of the health care industry.